Laura G. Giannetta
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Biphenotypic lung carcinoma with coexpression of TTF-1 and ΔNP63/P40 within most of the same individual cells: a further case confirming poor prognosis and a review of literature.
Journal: Pathologica
Published: December 05, 2023
What to do after immune-checkpoint inhibitors failure in advanced non-small cell lung cancer: an expert opinion and review.
Journal: Expert review of respiratory medicine
Published: October 11, 2023
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO).
Journal: ESMO open
Published: September 20, 2023
Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report.
Journal: JTO clinical and research reports
Published: May 22, 2023
Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.
Journal: Human vaccines & immunotherapeutics
Published: May 18, 2021
Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis.
Journal: Cancers
Published: March 24, 2021
Concurrent Small-Cell Transformation and Emergence of Trans-C797S and T790M Mutations Under Sequential Treatment With EGFR Inhibitors in Lung Adenocarcinoma.
Journal: JCO precision oncology
Published: December 01, 2019
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study.
Journal: Clinical lung cancer
Published: October 28, 2019
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Journal: Cancer discovery
Published: November 03, 2016
Last Updated: 09/26/2026